Jump to content

  • Log in with Facebook Log in with Twitter Log In with Google Sign In
  • Create Account

The MS PEOPLE UK Forum
Support, help, advice & information for Multiple Sclerosis. Ask questions & share experiences with people affected by MS.

Beating the drum for drug C yet again...


  • You cannot start a new topic
  • Please log in to reply
No replies to this topic

#1
RSS News

RSS News

    RSS News Feed Reader

  • Staff
  • 5,611 posts
  • Joined: 25-May 08
    Member: 792
  • Gender:Not Telling

Current mood: None chosen
Alvarez-Gonzalez CAdams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K. 
Ann Clin Transl Neurol 17 May 2017

Abstract
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium-enhancing lesions on T1 weighted MRI brain, within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a short course of subcutaneous cladribine 60 mg led to effective suppression of inflammatory activity and partial recovery with no short-term safety issues or adverse events.

We have been accused of beating the drum for cladribine a little too often. However, please read this case of one of my patients, consider the alternatives, and you may agree there aren't many with a comparable risk:benefit profile. The arguments are detailed in the discussion.

There are a few lessons beyond the effect of the drug used such as:

(i) Even in somebody with the clinical phenotype "primary progressive" MS, the principal mode of disability accrual may be through inflammatory lesions that look no different on MRI from relapsing MS.

(ii) Based on this and previous reports one should be very careful stopping a DMT known to be effective in relapsing MS, even when efficacy in the trial (INFORMS) was not significant *on the cohort level*. In our case, my impression would certainly be that fingolimod did work.

Unfortunately, our acknowledgement appears to have been lost in the course of proof editing the paper: We would like to thank Novartis for letting us use the clinical data of this participant, and for providing the lymphocyte counts, acquired during INFORMS.

CoI: multiple


View the full article


0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users


The MS People Forum is not responsible for advice or information supplied by members. We suggest you seek medical advice before trying anything.
Messages posted within the Forum express only the views of the author of the message and do not necessarily reflect the views of MS-People.com.
MS-People.com nor any person or entity associated with them will be held responsible for the contents, accuracy, completeness or validity of any information posted on the site.